A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease

2013134 citationsJournal Articlegold Open Access

Authors

ClinicalTrials.gov NCT00306215.

Good health and well-being

Published in: PLoS ONE

Volume 8, Issue 3, pp. e60094-e60094

Field-Weighted Citation Impact: 10.04